Transcriptional Activation of the Human Epidermal Growth Factor Receptor Promoter by Human P53
Overview
Authors
Affiliations
The human epidermal growth factor receptor (EGFR) promoter is activated by both wild-type and tumor-derived mutant p53. In this communication, we demonstrate that EGFR promoter sequence requirements for transactivation by wild-type and mutant p53 are different. Transient-expression assays with EGFR promoter deletions identified a wild-type human p53 response element, 5'-AGCTAGACGTCCGGGCAGCCCCCGGCG -3', from positions --265 to --239. Electrophoretic mobility shift analysis and DNase I footprinting assays indicated that wild-type p53 binds sequence specifically to the response element. Using circularly permuted DNA fragments containing the p53-binding site, we show that wild-type p53 binding induces DNA bending at this site. We further show that the EGFR promoter is also activated by tumor-derived p53 mutants p53-143A, p53-175H, p53-248W, p53-273H, and p53-281G. However, the transactivation by mutant p53 does not require the wild-type p53-binding site. The minimal EGFR promoter from positions --104 to --20 which does not contain the wild-type p53-binding site is transactivated by the p53 mutants but not by the wild-type protein, showing a difference in the mechanism of transactivation by wild-type and mutant p53. Transactivation of the EGFR promoter by p53 may represent a novel mechanism of cell growth regulation.
Zenz T, Jenke R, Oliinyk D, Noske S, Thieme R, Kahl T Neoplasia. 2025; 60:101121.
PMID: 39864337 PMC: 11802376. DOI: 10.1016/j.neo.2024.101121.
Seeling C, Dahlum S, Marienfeld R, Jan V, Rack B, Gerstenmaier U J Cancer Res Clin Oncol. 2025; 151(1):37.
PMID: 39820556 PMC: 11739273. DOI: 10.1007/s00432-024-06077-7.
Wen Y, Lin Y, Ho K, Yang Y, Lai F, Chu C Cell Mol Biol Lett. 2024; 29(1):126.
PMID: 39333870 PMC: 11429190. DOI: 10.1186/s11658-024-00643-0.
An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
Rodriguez S, Kamel A, Ciubotaru G, Onose G, Sevastre A, Sfredel V Int J Mol Sci. 2023; 24(13).
PMID: 37446288 PMC: 10341823. DOI: 10.3390/ijms241311110.
Medicinal chemistry perspective of pyrido[2,3-]pyrimidines as anticancer agents.
Kumar A, Bhagat K, Singh A, Singh H, Angre T, Verma A RSC Adv. 2023; 13(10):6872-6908.
PMID: 36865574 PMC: 9972360. DOI: 10.1039/d3ra00056g.